CEBPA and acute myeloid leukemia: Mutations of the CCAAT/enhancer binding protein alpha (CEBPA) gene have been associated with a favorable outcome in patients with AML, but mainly in those patients with cytogenetically normal AML (Renneville et al., 2009; Rockova et al., 2011).